Zhejiang Huahai Pharmaceutical Co Ltd
SSE:600521

Watchlist Manager
Zhejiang Huahai Pharmaceutical Co Ltd Logo
Zhejiang Huahai Pharmaceutical Co Ltd
SSE:600521
Watchlist
Price: 18.7 CNY -0.58%
Market Cap: 27.4B CNY
Have any thoughts about
Zhejiang Huahai Pharmaceutical Co Ltd?
Write Note
Zhejiang Huahai Pharmaceutical Co Ltd
/
Income Statement
/
Income from Continuing Operations

Zhejiang Huahai Pharmaceutical Co Ltd
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Zhejiang Huahai Pharmaceutical Co Ltd
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Zhejiang Huahai Pharmaceutical Co Ltd
SSE:600521
Income from Continuing Operations
¥1.1B
CAGR 3-Years
18%
CAGR 5-Years
23%
CAGR 10-Years
15%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Income from Continuing Operations
¥3.3B
CAGR 3-Years
8%
CAGR 5-Years
11%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Income from Continuing Operations
¥3.1B
CAGR 3-Years
9%
CAGR 5-Years
18%
CAGR 10-Years
24%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Income from Continuing Operations
¥5.4B
CAGR 3-Years
-5%
CAGR 5-Years
2%
CAGR 10-Years
14%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Income from Continuing Operations
¥4.3B
CAGR 3-Years
5%
CAGR 5-Years
3%
CAGR 10-Years
6%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Income from Continuing Operations
-¥780.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Zhejiang Huahai Pharmaceutical Co Ltd
Glance View

Market Cap
27.4B CNY
Industry
Pharmaceuticals

Zhejiang Huahai Pharmaceutical Co., Ltd., nestled in the vibrant economic landscape of China, has crafted a reputation as a pioneering force in the pharmaceutical industry. The company began its journey with a modest ambition: to establish itself as a reliable provider of Active Pharmaceutical Ingredients (APIs). Over the years, Huahai has broadened its horizons beyond APIs, expanding into the realm of finished dosage forms. This strategic diversification has enabled the company to control the entire value chain—from manufacturing raw pharmaceutical compounds to delivering final medicines ready for consumption. This integrated approach not only enhances quality control but also fortifies their market presence globally, allowing Huahai to cement its status as a formidable player in pharmaceutical exports. What sets Zhejiang Huahai apart is its steadfast commitment to innovation and compliance with international standards. The company channels considerable resources into research and development, focusing on therapeutic areas such as cardiovascular and central nervous system disorders. This devotion to R&D not only fuels the pipeline of new products but also enhances profitability by ensuring a steady stream of high-demand medications. Furthermore, Huahai's strategic partnerships with global pharmaceutical giants shape a dual-edged strategy of market expansion and shared expertise. By working closely with partners worldwide, Huahai ensures that its products remain at the cutting edge of medical advancements while maintaining regulatory compliance in diverse markets. This approach is what powers Huahai's steady revenue growth and robust competitive edge in the ever-evolving pharmaceutical sector.

Intrinsic Value
27.11 CNY
Undervaluation 31%
Intrinsic Value
Price
What is Intrinsic Value?

See Also

What is Zhejiang Huahai Pharmaceutical Co Ltd's Income from Continuing Operations?
Income from Continuing Operations
1.1B CNY

Based on the financial report for Sep 30, 2024, Zhejiang Huahai Pharmaceutical Co Ltd's Income from Continuing Operations amounts to 1.1B CNY.

What is Zhejiang Huahai Pharmaceutical Co Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
15%

Over the last year, the Income from Continuing Operations growth was 5%. The average annual Income from Continuing Operations growth rates for Zhejiang Huahai Pharmaceutical Co Ltd have been 18% over the past three years , 23% over the past five years , and 15% over the past ten years .

Back to Top
ALPHA SPREAD
Follow us
Join more than 210,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.